Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core
- PMID: 20451876
- PMCID: PMC2893399
- DOI: 10.1016/j.jalz.2010.03.012
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core
Abstract
Background: Our objectives are to facilitate autopsy consent, brain collection, and perform standardized neuropathologic assessments of all Alzheimer's Disease Neuroimaging Initiative (ADNI) participants who come to autopsy at the 58 ADNI sites in the USA and Canada.
Methods: Building on the expertise and resources of the existing Alzheimer's Disease Research Center (ADRC) at Washington University School of Medicine, St. Louis, MO, a Neuropathology Core (NPC) to serve ADNI was established with one new highly motivated research coordinator. The ADNI-NPC coordinator provides training materials and protocols to assist clinicians at ADNI sites in obtaining voluntary consent for brain autopsy in ADNI participants. Secondly, the ADNI-NPC maintains a central laboratory to provide uniform neuropathologic assessments using the operational criteria for the classification of AD and other pathologies defined by the National Alzheimer Coordinating Center (NACC). Thirdly, the ADNI-NPC maintains a state-of-the-art brain bank of ADNI-derived brain tissue to promote biomarker and multi-disciplinary clinicopathologic studies.
Results: During the initial year of funding of the ADNI Neuropathology Core, there was notable improvement in the autopsy rate to 44.4%. In the most recent year of funding (September 1(st), 2008 to August 31(st) 2009), our autopsy rate improved to 71.5%. Although the overall numbers to date are small, these data demonstrate that the Neuropathology Core has established the administrative organization with the participating sites to harvest brains from ADNI participants who come to autopsy.
Conclusions: Within two years of operation, the Neuropathology Core has: (1) implemented a protocol to solicit permission for brain autopsy in ADNI participants at all 58 sites who die and (2) to send appropriate brain tissue from the decedents to the Neuropathology Core for a standardized, uniform, and state-of-the-art neuropathologic assessment. The benefit to ADNI of the implementation of the NPC is very clear. Prior to the establishment of the NPC in September 2007, there were 6 deaths but no autopsies in ADNI participants. Subsequent to the establishment of the Core there have been 17 deaths of ADNI participants and 10 autopsies. Hence, the autopsy rate has gone from 0% to 59%. The third major accomplishment is the detection of co-existent pathologies with AD in the autopsied cases. It is possible that these co-morbidities may contribute to any variance in ADNI data.
Copyright 2010 The Alzheimer
Similar articles
-
Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants.Alzheimers Dement. 2015 Jul;11(7):815-22. doi: 10.1016/j.jalz.2015.05.010. Alzheimers Dement. 2015. PMID: 26194314 Free PMC article. Review.
-
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).Neuropathology. 2015 Aug;35(4):390-400. doi: 10.1111/neup.12205. Epub 2015 May 12. Neuropathology. 2015. PMID: 25964057 Free PMC article.
-
The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update.Alzheimers Dement. 2024 Nov;20(11):7859-7870. doi: 10.1002/alz.14253. Epub 2024 Oct 1. Alzheimers Dement. 2024. PMID: 39351959 Free PMC article.
-
Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.Neurobiol Aging. 2015 Sep;36(9):2501-8. doi: 10.1016/j.neurobiolaging.2015.05.021. Epub 2015 Jun 6. Neurobiol Aging. 2015. PMID: 26119224 Free PMC article.
-
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006. Alzheimers Dement. 2010. PMID: 20451872 Free PMC article. Review.
Cited by
-
Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease.Sci Rep. 2016 Nov 2;6:35636. doi: 10.1038/srep35636. Sci Rep. 2016. PMID: 27805057 Free PMC article.
-
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Alzheimers Dement. 2012. PMID: 22047634 Free PMC article. Review.
-
Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.Ann Clin Transl Neurol. 2015 Oct;2(10):949-59. doi: 10.1002/acn3.246. Epub 2015 Sep 12. Ann Clin Transl Neurol. 2015. PMID: 26478895 Free PMC article.
-
Pathologic correlates of supranuclear gaze palsy with parkinsonism.Parkinsonism Relat Disord. 2017 May;38:68-71. doi: 10.1016/j.parkreldis.2017.02.027. Epub 2017 Feb 24. Parkinsonism Relat Disord. 2017. PMID: 28256434 Free PMC article.
-
Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants.Alzheimers Dement. 2015 Jul;11(7):815-22. doi: 10.1016/j.jalz.2015.05.010. Alzheimers Dement. 2015. PMID: 26194314 Free PMC article. Review.
References
-
- Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–23. - PubMed
-
- Mirra SS, Gearing M, McKeel DW, Jr, Crain BJ, Hughes JP, van Belle G, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) J Neuropathol Exp Neurol. 1994;53:303–15. - PubMed
-
- Alafuzoff I, Pikkarainen M, Al Sarraj S, Arzberger T, Bell J, Bodi I, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740–57. - PubMed
-
- Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097–105. - PubMed
-
- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–86. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical